arrow
C

Carlo Resteghini

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:22
被引数:1,754

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck

可切除的头颈部鳞状细胞癌新辅助免疫治疗的目标和反应标准的标准化

2026-06-240
OAAI
Liquid biopsies for BRAF V600E assessment and monitoring in anaplastic thyroid carcinoma: a real-world study of a tertiary cancer center

液态活检用于评估和监测间变性甲状腺癌中的BRAF V600E:一项三级癌症中心的真实世界研究

2026-06-230
OAAI
Radiological–pathological correlation of Head and Neck Cancer International Group (HNCIG) criteria for extranodal extension across imaging modalities: A retrospective cohort study

头颈癌国际协作组(HNCIG)关于跨影像学模式的结外侵犯标准的放射学-病理学相关性:一项回顾性队列研究

2026-04-140
PRE
Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study

分子检测和精准肿瘤学对晚期甲状腺癌患者的影响:一项OrienTHYring真实世界研究

2025-10-290
OAAI
A multicenter retrospective analysis of recurrent/metastatic nasopharyngeal cancer from non-endemic areas: results in the pre-immunotherapy era

非流行区复发性/转移性鼻咽癌的多中心回顾性分析:免疫治疗时代前的结果

2025-09-020
PRE
Systemic anticancer therapy during end of life in head and neck squamous cell carcinoma patients. A retrospective single center study.

头颈部鳞状细胞癌患者临终期系统性抗肿瘤治疗。一项回顾性单中心研究。

2025-08-290
OAAI
The interplay of hypoxia, inflammation, and microbiota as indicators of malignant transformation in oral potentially malignant disorders

缺氧、炎症和微生物群之间的相互作用作为口腔癌前病变中恶性转化的指标

2025-08-080
OA
Safety of neoadjuvant PARP inhibitor and immunotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma (PRIME H&N Study)

局部晚期HPV阴性头颈鳞状细胞癌中,新辅助PARP抑制剂联合免疫疗法的安全性(PRIME H&N研究)

2024-09-010
PRE
Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: Implications for improving treatment modalities

EBV流行和非流行地区的爱泼斯坦-巴尔病毒 (EBV) 相关鼻咽癌的肿瘤分子景观: 对改善治疗方式的影响

2024-03-014
OAAI
Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience
2023-11-014
OAAI
Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure
2023-09-133
OAAI